The PENTO Protocol in Medication-related Osteonecrosis of the Jaw
Medication-related osteonecrosis of the jaw (MRONJ) occurs after taking bisphosphonates or targeted therapies. It leads to a significant decrease in quality of life with pain, eating and chewing disorders, and malnutrition. Current treatments are only partially effective. PENTO (pentoxifylline and tocopherol) has been shown to be effective in maxillary osteoradionecrosis. The objective of this study is to evaluate the proportion of bone recovery in patients receiving PENTO in MRONJ at 12 months.
• Age greater than or equal to 18 years
• Current or past treatment with bisphosphonates (oral or IV) and/or targeted therapies (denosumab, bevacizumab)
• Signs and symptoms for more than 8S with confirmation that the signs and symptoms are not of dental origin
• AAOMS Stage 2 MRONJ
• For patients of childbearing age, effective contraception is required